Physician profile
Mark C Vital
NPI 1073515912
$68,589.93
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $452 · 2021: $15K · 2022: $10K · 2023: $21K · 2024: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $25K · Travel and Lodging: $3,286 · Food and Beverage: $2,636 · Education: $47.61 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $24,775.00 |
| Travel and Lodging | $3,285.80 |
| Food and Beverage | $2,635.50 |
| Education | $47.61 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $40,009.31 | 2019-2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13,918.73 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $3,841.09 | 2022-2024 | Miebo, Vyzulta, Xiidra |
| Sight Sciences, INC. | $3,081.94 | 2020-2022 | |
| Biotissue Holdings INC. | $2,151.65 | 2019-2024 | |
| Eyevance Pharmaceuticals LLC | $1,825.40 | 2019-2023 | Flarex |
| Glaukos Corporation | $771.35 | 2021-2024 | Photrexa Cross-Linking Kit, Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Oyster Point Pharma, INC. | $443.50 | 2022-2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $423.17 | 2020-2024 | Acthar |
| Abbvie INC. | $410.82 | 2022-2024 | Lumigan, Durysta, Vuity |
| Kala Pharmaceuticals, INC. | $319.87 | 2019-2022 | |
| Rxsight INC | $307.69 | 2021-2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $305.65 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $157.97 | 2019-2022 | |
| Alcon Vision LLC | $96.56 | 2019-2023 | Clareon, Argos, Rocklatan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $88.74 | 2024 | Breztri |
| Optos, INC. | $63.70 | 2022 | |
| Shire North American Group INC | $52.21 | 2019 | |
| Mallinckrodt Enterprises LLC | $47.12 | 2019 | |
| Santen INC. | $45.25 | 2023 | Verkazia |
| Allergan, INC. | $44.09 | 2021 | |
| Haag-Streit USA, INC. | $29.77 | 2023 | |
| Harrow Eye, LLC | $29.29 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $28.12 | 2024 | Xdemvy |
| Eyepoint US, INC. | $21.80 | 2019 | |
| Aerie Pharmaceuticals, INC. | $20.33 | 2021 | |
| Carl Zeiss Meditec, INC. | $16.25 | 2019 | |
| Horizon Therapeutics Plc | $16.03 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $13.41 | 2020 | |
| Beaver-Visitec International, INC. | $9.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vital listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.